Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

141. Schizophrenia: aripiprazole prolonged-release suspension for injection

Schizophrenia: aripiprazole prolonged-release suspension for injection Schizophrenia: aripipr Schizophrenia: aripiprazole prolonged-release azole prolonged-release suspension for injection suspension for injection Evidence summary Published: 26 March 2014 nice.org.uk/guidance/esnm39 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in March 2014. See summaries of product characteristics (SPCs), British national formulary (...) (BNF) or the MHRA or NICE websites for up-to-date information. Summary Aripiprazole prolonged-release suspension for injection is licensed for maintenance treatment of schizophrenia in adults whose condition has been stabilised with oral aripiprazole. It was launched in the UK in January 2014. In 2 double-blind, randomised controlled trials (RCTs; n=403 and n=662), once-monthly aripiprazole 400 mg prolonged-release injection was shown to be superior to placebo and non-inferior to oral aripiprazole

National Institute for Health and Clinical Excellence - Advice2014

142. Schizophrenia: lurasidone

Schizophrenia: lurasidone Schizophrenia: lur Schizophrenia: lurasidone asidone Evidence summary Published: 23 September 2014 nice.org.uk/guidance/esnm48 pathways This advice replaces ESNM15. K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in September 2014. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary Lurasidone (Latuda, Sunovion (...) Pharmaceuticals Europe Ltd) is licensed for treating schizophrenia in adults aged 18 years and over. It was launched in the UK in August 2014. Evidence from 5 short- term and 3 long-term studies suggests that lurasidone is effective at treating psychotic symptoms, and at preventing relapse in adults with schizophrenia. The European Public Assessment Report [EPAR] for lurasidone states that the adverse event profile of lurasidone is similar to that for other second-generation antipsychotics, the most common

National Institute for Health and Clinical Excellence - Advice2014

143. Community-based intervention for people with schizophrenia successfully provided by supervised community health workers in a low-resource setting

Community-based intervention for people with schizophrenia successfully provided by supervised community health workers in a low-resource setting Community-based intervention for people with schizophrenia successfully provided by supervised community health workers in a low-resource setting | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Community-based intervention for people with schizophrenia successfully provided by supervised community health workers in a low-resource setting Article Text Miscellaneous Community-based intervention for people

Evidence-Based Mental Health2014

144. Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered

Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered Article Text Pharmacological interventions Paliperidone depot

Evidence-Based Mental Health2014

145. Supported Employment for Schizophrenia

Supported Employment for Schizophrenia Supported Employment for Schizophrenia | Society of Clinical Psychology Supported Employment for Schizophrenia Status: Strong Research Support Description Supported Employment (SE; also known as Individual Placement and Support) is an approach to vocational rehabilitation (VR) adapted for individuals with serious mental illness. Supported employment emphasizes the integration of employment and mental health services, rapid placement of individuals (...) into jobs in the community, individualized job development, and ongoing job supports. Rather than segregating vocational rehabilitation and mental health services, supported employment specialists are part of the client’s treatment team. The goal of supported employment is to assist the person with schizophrenia in attaining competitive, community-based employment. As compared to more traditional VR approaches for this population (e.g. clubhouse models, transitional employment), the community-based

Society of Clinical Psychology2014

146. Social Skills Training for Schizophrenia

Social Skills Training for Schizophrenia Social Skills Training (SST) for Schizophrenia | Society of Clinical Psychology Social Skills Training (SST) for Schizophrenia Status: Strong Research Support Description SST uses the principles of behavior therapy to teach communication skills, assertiveness skills, and other skills related to disease management and independent living. SST is usually conducted in small groups that are ideally led by two co-therapists. Skills are broken down into several (...) on the needs of the client(s) and the treatment setting. SST may be even more helpful when supplemented with community-based practice opportunities and support. Key References (in reverse chronological order) Kopelowicz, A., Liberman, R.P., Zarate, R. (2006) Recent advances in social skills training for schizophrenia. Schizophrenia Bulletin, 32, pS12-S23. Bellack, AS (2002). Skills training for people with severe mental illness. Psychiatric Rehabilitation, 7, 375-391 Glynn, S.M., Marder, S.R., Liberman

Society of Clinical Psychology2014

147. Social Learning/Token Economy Programs for Schizophrenia

Social Learning/Token Economy Programs for Schizophrenia Social Learning/Token Economy Programs for Schizophrenia | Society of Clinical Psychology Social Learning/Token Economy Programs for Schizophrenia Status: Strong Research Support Description Token economy programs are generally used in long-term care setting such as long-stay inpatient units and residential care settings, but can be adapted for shorter stay and less intensive treatment programs as well. They are comprehensive behavioral (...) Services , 46(12): 1258-1263, 1995. Dickerson, F.D., Tenhula, W.N., & Green-Paden, L. (2005). The token economy for schizophrenia: Review of the literature and recommendations for future research. Schizophrenia Research . 75 (2-3): 405-416. Clinical Resources Ayllon, T., and Azrin, N.H. The Token Economy : A Motivational System for Therapy and Rehabilitation . Englewood Cliffs, NJ: Prentice Hall, 1968. Paul, G.L., and Lentz, R.J. Psychosocial Treatment of Chronic Mental Patients: Milieu versus Social

Society of Clinical Psychology2014

148. Illness Management and Recovery for Schizophrenia

Illness Management and Recovery for Schizophrenia Illness Management and Recovery (IMR) for Schizophrenia | Society of Clinical Psychology Illness Management and Recovery (IMR) for Schizophrenia Status: Modest Research Support Description Illness Management and Recovery (IMR) focuses on teaching illness self-management to persons with serious mental illness. The emphasis is on recovery by helping clients set and pursue personally meaningful goals. IMR combines 1) psychoeducation about mental (...) , development, and preliminary findings. Schizophrenia Bulletin, 32, p S32-S43. Gingerich, S. & Mueser, K.T. (2005). Illness management and recovery. In Drake, R.E., Merrens, M.R. & Lynde, D.E. (Eds). Evidence-based mental health practice: A textbook. New York, Norton. Clinical Resources Velligan, DI (2000). Cognitive Adaptation Training: The Use of Compensatory Strategies in the Psychosocial Rehabilitation of Patients with Schizophrenia. (Manual for therapists) UTHSCSA, Department of Psychiatry. Links

Society of Clinical Psychology2014

149. Cognitive Remediation for Schizophrenia

Cognitive Remediation for Schizophrenia Cognitive Remediation for Schizophrenia | Society of Clinical Psychology Cognitive Remediation for Schizophrenia Status: Strong Research Support Description Cognitive functions such as executive function, learning & memory, processing speed, and sustained attention are frequently impaired and play an important role in the functional impairments seen in schizophrenia. Cognitive remediation (CR) or cognitive rehabilitation interventions are designed (...) to improve cognitive function through repeated practice of cognitive tasks and / or strategy training. CR interventions are typically time-limited. They can be conducted individually or in groups. Some involve extensive use of computers while others focus primarily on paper-and-pencil tasks. Most CR interventions take into account the motivational and emotional deficits that are often present in schizophrenia as well. The goal of CR is to improve cognitive function. Research has shown small to medium

Society of Clinical Psychology2014

150. Cognitive Behavioral Therapy for Schizophrenia

Cognitive Behavioral Therapy for Schizophrenia Cognitive Behavioral Therapy (CBT) for Schizophrenia | Society of Clinical Psychology Cognitive Behavioral Therapy (CBT) for Schizophrenia Status: Strong Research Support Description Similar to Cognitive-Behavioral Therapy (CBT) for other types of problems, CBT for schizophrenia involves establishing a collaborative therapeutic relationship, developing a shared understanding of the problem, setting goals, and teaching the person techniques (...) or strategies to reduce or manage their symptoms. Therapy is usually conducted in individual sessions and is time-limited (typically several months). The goal is not to “cure” schizophrenia, but rather to improve the person’s ability to function independently, manage their schizophrenia, and to reduce the distress they experience in their daily life. Specific CBT approaches used in treating schizophrenia include cognitive restructuring, behavioral experiments / reality testing, self-monitoring and coping

Society of Clinical Psychology2014

151. Cognitive Adaptation Training for Schizophrenia

Cognitive Adaptation Training for Schizophrenia Cognitive Adaptation Training (CAT) for Schizophrenia | Society of Clinical Psychology Cognitive Adaptation Training (CAT) for Schizophrenia Status: Modest Research Support Description Cognitive Adaptation Training (CAT) is designed to improve everyday functioning by teaching the individual with schizophrenia to use strategies that compensate for (or work around) the cognitive deficits associated with schizophrenia. Treatment plans are based (...) place over several months and includes multiple visits to the client’s home and/or workplace. Key References (in reverse chronological order) Velligan , DI, Bow-Thomas, C.C., Huntzinger, C., Ledbetter, N., Prihoda, T.J., & Miller, A.L. (2000). Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. American Journal of Psychiatry, 157(8), 1317-1323. Velligan, D.I., Prihoda, T.J., Ritch, J.L., Maples, N., Bow-Thomas, C.C

Society of Clinical Psychology2014

152. Assertive Community Treatment for Schizophrenia

Assertive Community Treatment for Schizophrenia Assertive Community Treatment (ACT) for Schizophrenia | Society of Clinical Psychology Assertive Community Treatment (ACT) for Schizophrenia Status: Strong Research Support Description ACT is a multidisciplinary team approach to intensive case management in which the team members share a caseload, have a high frequency of patient contact (typically at least once a week), low patient to staff ratios, and provide outreach to patients (...) : the effect on hospital use and costs. Health Services Research , 34(2): 577-601, 1999. Lehman A.F.; Dixon L.B.; Kernan E.; DeForge B.R.; Postrado L.T. A randomized trial of assertive community treatment for homeless persons with severe mental illness. Archives of General Psychiatry , 54:1038-1043, 1997. Scott J.; Dixon L. Assertive community treatment and case management. Schizophrenia Bulletin 21(4):657-68, 1995. Burns B.J.; Santos, A.B. Assertive community treatment: an update of randomized trials

Society of Clinical Psychology2014

153. Among untreated violent offenders with schizophrenia, persecutory delusions are associated with violent recidivism

Among untreated violent offenders with schizophrenia, persecutory delusions are associated with violent recidivism Among untreated violent offenders with schizophrenia, persecutory delusions are associated with violent recidivism | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Among untreated violent offenders with schizophrenia, persecutory delusions are associated with violent recidivism Article Text Causes and risk factors Among untreated violent offenders with schizophrenia, persecutory delusions are associated with violent recidivism Sheilagh

Evidence-Based Mental Health2014

154. Case control study: People with schizophrenia are more likely to have a mother who smoked during pregnancy than people without the condition

Case control study: People with schizophrenia are more likely to have a mother who smoked during pregnancy than people without the condition People with schizophrenia are more likely to have a mother who smoked during pregnancy than people without the condition | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here People with schizophrenia are more likely to have a mother who smoked during pregnancy than people without the condition Article Text Mental health Case control study People with schizophrenia are more likely to have a mother who smoked during

Evidence-Based Nursing (Requires free registration)2014 Full Text: Link to full Text with Trip Pro

155. Metformin for weight loss in schizophrenia: safe but not a panacea

Metformin for weight loss in schizophrenia: safe but not a panacea Metformin for weight loss in schizophrenia: safe but not a panacea | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin for weight loss in schizophrenia: safe but not a panacea Article Text Pharmacological interventions Metformin for weight loss in schizophrenia: safe but not a panacea Cenk Tek 1 , Lydia Chwastiak 2 Statistics from Altmetric.com No Altmetric data available for this article. What is already known on this topic? Obesity and diabetes rates are two to three times

Evidence-Based Mental Health2014

156. Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines

Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Long-term 5HT3 antagonist use (...) for schizophrenia: clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions One systematic review and six randomized controlled trials were identified regarding the use of 5HT3 antagonists for the treatment of schizophrenia. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Schizophrenia; Schizophrenic Psychology; Serotonin 5-HT3 Receptor Antagonistss Language Published English Country

Health Technology Assessment (HTA) Database.2014

157. Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia.

Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia. BACKGROUND: Treatment of schizophrenia depends heavily on neuroleptic drugs. Hypersalivation is a common side effect when people with schizophrenia are treated with neuroleptic drugs. Hypersalivation can be an embarrassing and stigmatising problem, can affect quality of life and can result in discontinuation of neuroleptic treatment. It can also be difficult to treat. OBJECTIVES (...) : To summarise the best available evidence of the effects of anticholinergic drugs in the treatment of non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia. Clozapine-induced hypersalivation has been addressed in another Cochrane review. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (15 November 2012) and inspected references of all identified studies for further relevant studies. We were to contact the first author of each included study

Cochrane2013

158. Schizophrenia: an integrated sociodevelopmental-cognitive model.

Schizophrenia: an integrated sociodevelopmental-cognitive model. Schizophrenia remains a major burden on patients and society. The dopamine hypothesis attempts to explain the pathogenic mechanisms of the disorder, and the neurodevelopmental hypothesis the origins. In the past 10 years an alternative, the cognitive model, has gained popularity. However, the first two theories have not been satisfactorily integrated, and the most influential iteration of the cognitive model makes no mention (...) of salience to stimuli, which are then misinterpreted by the biased cognitive processes. The resulting paranoia and hallucinations in turn cause further stress, and eventually repeated dopamine dysregulation hardwires the psychotic beliefs. Finally, we consider the implications of this model for understanding and treatment of schizophrenia. Copyright © 2014 Elsevier Ltd. All rights reserved.

Lancet2013 Full Text: Link to full Text with Trip Pro

159. Add-on Treatment of Benzoate for Schizophrenia: A Randomized, Double-blind, Placebo-Controlled Trial of d-Amino Acid Oxidase Inhibitor

Add-on Treatment of Benzoate for Schizophrenia: A Randomized, Double-blind, Placebo-Controlled Trial of d-Amino Acid Oxidase Inhibitor 24089054 2013 12 05 2014 02 24 2014 12 24 2168-6238 70 12 2013 Dec JAMA psychiatry JAMA Psychiatry Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. 1267-75 10.1001/jamapsychiatry.2013.2159 In addition to dopaminergic hyperactivity, hypofunction of the N-methyl-d-aspartate (...) receptor (NMDAR) has an important role in the pathophysiology of schizophrenia. Enhancing NMDAR-mediated neurotransmission is considered a novel treatment approach. To date, several trials on adjuvant NMDA-enhancing agents have revealed beneficial, but limited, efficacy for positive and negative symptoms and cognition. Another method to enhance NMDA function is to raise the levels of d-amino acids by blocking their metabolism. Sodium benzoate is a d-amino acid oxidase inhibitor. To examine the clinical

EvidenceUpdates2013

160. Assisting Social Security Disability Insurance Beneficiaries With Schizophrenia, Bipolar Disorder, or Major Depression in Returning to Work

Assisting Social Security Disability Insurance Beneficiaries With Schizophrenia, Bipolar Disorder, or Major Depression in Returning to Work 23929355 2013 12 06 2014 02 17 2014 11 14 1535-7228 170 12 2013 Dec The American journal of psychiatry Am J Psychiatry Assisting Social Security Disability Insurance beneficiaries with schizophrenia, bipolar disorder, or major depression in returning to work. 1433-41 10.1176/appi.ajp.2013.13020214 People with psychiatric impairments (primarily schizophrenia (...) with elimination of barriers by providing complete health insurance coverage (with no out-of-pocket expenses) and suspending disability reviews. The control group received usual services. Paid employment was the primary outcome measure, and overall mental health and quality of life were secondary outcome measures. Overall, 2,059 SSDI beneficiaries with schizophrenia, bipolar disorder, or depression in 23 cities participated in the 2-year intervention. The teams implemented the intervention package

EvidenceUpdates2013